All targets
Target workspace
Lysosomal pathway
Lysosomal pH and autophagy modulation.
Pathway & druggability
Autophagy / antigen processing
Druggability: Moderate (chloroquine analogs)
Evidence behind this
Confidence score12%
Signal strength: Very LowLevel 1 (negative RCTs)
Evidence grade
Insufficient Evidence
Large RCTs (RECOVERY, SOLIDARITY) showed no mortality benefit; not recommended.
Mechanism
Proposed antiviral and immunomodulatory effects via lysosomal pH and autophagy.
clinical trialmeta analysisMultiple Phase III (negative)
Authoritative sources
AI-generated summary
Generated March 15, 2026Last verified June 29, 2026
Despite early enthusiasm, hydroxychloroquine lacks efficacy for COVID-19. RECOVERY and SOLIDARITY trials demonstrated no benefit; WHO recommends against use. Important negative repurposing example.
Source papers
- WHO Solidarity Consortium, NEJM 2021
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.